BOSTON - Haemonetics Corporation (NYSE:HAE), a company specializing in medical technology, has announced the full market release of the VASCADE MVP XL venous closure system in the United States. This latest addition to the VASCADE portfolio is designed to enhance patient outcomes by offering an advanced solution for vascular closure.
The VASCADE MVP XL system is distinguished by its use of 58% more collagen and a larger disc compared to its predecessor, the VASCADE MVP system.
It is tailored for procedures that require larger sheaths, such as cryoablation, Pulsed Field Ablation, and Left Atrial Appendage Closure. The system has been employed by around 80 physicians in over 30 hospitals during its limited market release since June 2024.
President of Global Hospital at Haemonetics, Stew Strong, expressed enthusiasm about the positive feedback received from the limited release and highlighted the company's goal to become a leader in vascular closure. Haemonetics is also conducting clinical trials to expand the indications for the VASCADE MVP XL system to cater to even larger access points.
The VASCADE portfolio also includes devices for smaller and mid-bore femoral arterial and venous closures. These products are part of Haemonetics' suite of medical solutions aimed at improving patient care and reducing healthcare costs. The company's offerings extend across blood and plasma component collection, surgical suite solutions, and hospital transfusion services.
Haemonetics has a history of filing periodic reports with the U.S. Securities and Exchange Commission, where more detailed information on these factors can be found.
This announcement is based on a press release statement from Haemonetics Corporation.
InvestingPro Insights
As Haemonetics Corporation (NYSE:HAE) advances its medical technology offerings with the full market release of the VASCADE MVP XL venous closure system, investors are closely monitoring the company's financial health and stock performance. According to InvestingPro data, Haemonetics has a market capitalization of $3.75 billion, demonstrating its substantial presence in the medical technology sector. The company's price-to-earnings (P/E) ratio stands at 33.29, which suggests a higher valuation compared to some industry peers. Despite this, the adjusted P/E ratio for the last twelve months as of Q1 2025 is at a more moderate 22.19. Additionally, Haemonetics has shown a solid revenue growth of 9.47% over the last twelve months as of Q1 2025, underlining the company's ability to expand its financial top line.
InvestingPro Tips highlight that Haemonetics' stock is currently trading near its 52-week low and is considered to be in oversold territory based on the Relative Strength Index (RSI). This could potentially signal a buying opportunity for investors who are bullish on the company’s prospects, especially considering that analysts predict Haemonetics will be profitable this year. Furthermore, the company's financial stability is supported by the fact that its cash flows can sufficiently cover interest payments and its liquid assets exceed its short-term obligations.
For investors seeking more detailed analysis, there are additional InvestingPro Tips available, which can be accessed through the dedicated InvestingPro platform for Haemonetics at https://www.investing.com/pro/HAE. These tips provide deeper insights into the company's financial metrics and stock performance, offering valuable information for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.